Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bearish -35

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies ...

Clinical trial results Drug safety AI-generated analysis

🛑 Bristol-Myers Squibb paused enrollment in its zola-cel autoimmune CAR-T program following observations of transient and reversible inflammatory events.

💀 No patient deaths were reported for BMY's zola-cel trials, distinguishing the safety profile from Novartis' recent fatal immune reactions.

📉 Hedge fund interest in BMY decreased in Q2 2026, with position value dropping from $5.97 billion to $4.79 billion as investors reacted to pipeline uncertainty.

⏳ The company paused only new enrollment rather than halting all trial activities, suggesting a potentially clearer path toward restarting studies if safety protocols are adjusted.

🔬 BMY described the inflammatory events as transient and reversible, indicating a less severe disclosed safety situation compared to Novartis' fatal cases.

⚖️ The pause creates governance concerns regarding disclosure timelines, as BMY waited three months before informing the public despite early June internal notifications.

Bullish Signals
  • The company reported that observed inflammatory events were transient and reversible, suggesting a manageable safety profile compared to fatal outcomes seen in competitors.
  • Bristol-Myers Squibb paused only new enrollment rather than stopping all trial activities, preserving ongoing data collection and offering a clearer path toward restarting studies.
Risk Factors
  • Enrollment was paused in the zola-cel autoimmune CAR-T program following observations of inflammatory events, creating immediate development delays.
  • The company waited approximately three months to inform the public about safety issues despite internal knowledge in early June, raising governance and reputational concerns.
  • Hedge fund interest declined significantly in Q2 2026, with position value dropping from $5.97 billion to $4.79 billion, reflecting investor caution regarding pipeline setbacks.
Full Analysis
On September 1, 2026, Bristol-Myers Squibb (BMY) paused enrollment in its competing CAR-T program, zola-cel, for autoimmune and neurological conditions. The company cited precautionary measures following observations of 'transient and reversible' inflammatory events, explicitly noting that no patient deaths occurred during this period. Unlike Novartis, which halted eight trials after three patient deaths from a severe immune reaction, BMY's response is narrower in scope and severity. The firm has not stopped all aspects of its trials but rather limited new enrollment while conducting a safety review to identify effective monitoring or treatment strategies that could allow for a restart. Market positioning data reveals a divergence in investor sentiment ahead of the public disclosure. Hedge fund interest in BMY declined significantly, with holder counts dropping from 83 to 74 and position value falling from $5.97 billion to $4.79 billion in the second quarter, contrasting with Novartis which saw increased hedge fund accumulation prior to its own setbacks becoming public.